drugset / Trial / NCT01201772

Prasugrel Re-load Strategies

NCT01201772

Phase 4 Completed 65 enrolled University of Florida
RandomizedParallel-groupOpen-labelDiagnostic

Summary

A higher degree of platelet inhibition remains the goal of peri-interventional and long-term anti-thrombotic therapy in patients with coronary artery disease. In clinical practice, patients undergoing percutaneous coronary intervention with stent implantation who are already on clopidogrel therapy get re-loaded with clopidogrel. This is based on prior observations showing that higher inhibition of platelet aggregation may be achieved by giving a loading dose of clopidogrel in patients with coronary artery disease while on chronic clopidogrel therapy. However, to date it is unknown if greater inhibition of platelet aggregation can be achieved by adding a prasugrel loading dose in patients on chronic prasugrel therapy. Therefore, understanding the pharmacodynamic implications of a prasugrel re-load strategy in patients on already on chronic prasugrel therapy will be useful.

Timeline

Start
2010-08
Primary completion
2011-05
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prasugrel Small molecule 10 mg
Comparator Prasugrel Small molecule 30 mg
Comparator Prasugrel Small molecule 60 mg